2007 AHA Satellite Symposium: Refractory Angina — Options for the No-Option Patient

Refractory Angina — Options for the No-Option Patient

November 4, 2007, Orlando, Florida

Patients with refractory angina present a conundrum to the practicing cardiologist, because they are often difficult to manage. In this symposium, you will hear the latest about the management of refractory angina from leading researchers and clinicians. Pharmacological, device, and cellular therapies to deal with this important and problematic disease will be reviewed. Case studies and novel therapies being investigated will be presented.

Agenda

Slides not available
Cellular Therapy
Douglas W. Losordo, MD, FACC
Director, Feinberg Cardiovascular Research Institute
Eileen M. Foell Professor of Heart Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Gene Therapy
Timothy D. Henry, MD, FACC
Director of Research, Minneapolis Heart Institute Foundation
Interventional Cardiologist, Minneapolis Heart Institute
Associate Professor of Medicine, University of Minnesota School of Medicine, MN
Novel Pharmaceutical Agents
Carl J. Pepine, MD, MACC
Eminent Scholar, AHA – Suncoast Chapter Chair
Professor of Medicine
Chief, Division of Cardiovascular Medicine
University of Florida College of Medicine
Gainesville, FL
Enhanced External Counterpulsation (EECP)
Gregory W. Barsness, MD
Director, Interventional Cardiology Training Program
Consultant, Cardiovascular Diseases,
Internal Medicine and Radiology
Mayo Clinic
Rochester, MN
Case Presentations
Rachel Olson, RN, MS, CCRC
Senior Research Nurse Clinician
Minneapolis Heart Institute Foundation
Minneapolis, MN
 
Daniel Satran, MD
Interventional Cardiology Fellow
University of Minnesota
Minneapolis, MN
After attending this symposium, participants will be able to:
 
1.   Explain the definition, epidemiology, and natural history of patients with refractory angina.
2.   Summarize the rationale and trial results of cellular therapy for patients with refractory angina.
3.   Describe current available clinical and research options for refractory angina, which include cellular therapies, pharmacologic therapy (ranolazine), and devices such as enhanced external counterpulsation for refractory angina.